Patents by Inventor William John Pitts

William John Pitts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidine inhibitors of phosphodiesterase (PDE) 7
    Patent number: 7087614
    Abstract: Pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula wherein R1, R2, Z, J and L are described herein, and analogs thereof are provided which are useful in treating T-cell mediated diseases.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: August 8, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Junqing Guo, Joseph Barbosa, William John Pitts, Marianne Carlsen, Claude Quesnelle, Marco Dodier
  • Pyrimidine inhibitors of phosphodiesterase (PDE) 7
    Publication number: 20030162802
    Abstract: Pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula 1
    Type: Application
    Filed: June 17, 2002
    Publication date: August 28, 2003
    Inventors: Junqing Guo, Joseph Barbosa, William John Pitts, Marianne Carlsen, Claude Quesnelle, Marco Dodier
  • Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 6110910
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: August 29, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Prostaglandin synthase inhibitors
    Patent number: 5932586
    Abstract: This invention relates to ortho substituted phenyl compounds as inhibitors of prostaglandin synthase, to pharmaceutical compositions comprising such compounds and to methods of using such compounds as antiinflammatory and antipyretic agents.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: August 3, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Douglas Guy Batt, Donald Joseph Phillip Pinto, Michael James Orwat, Joseph James Petraitis, William John Pitts
  • Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5874441
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: February 23, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Integrin receptor antagonists
    Patent number: 5710159
    Abstract: This invention relates to novel heterocycle compounds including but not limited to 3-?3-?3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: January 20, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Matthew Ernst Voss, Prabhakar Kondaji Jadhav, Joanne Marie Smallheer, Douglas Guy Batt, William John Pitts, John Wityak
  • Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5639759
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 17, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt